Touchefeu, Y. http://orcid.org/0000-0001-8421-3182
Bailly, C.
Frampas, E.
Eugène, T.
Rousseau, C.
Bourgeois, M.
Bossard, C.
Faivre-Chauvet, A.
Rauscher, A.
Masson, D.
David, A.
Cerato, E.
Carlier, T.
Sharkey, R. M.
Goldenberg, D. M.
Barbet, J.
Kraeber-Bodere, F.
Bodet-Milin, C.
Funding for this research was provided by:
Agence Nationale de la Recherche (Investissements d’Avenir” IRON Labex ANR-11-LABX-0018-01, ArronaxPlus Equipex ANR-11-EQPX-0004)
Direction Générale de l’offre de Soins (INCa-DGOS-Inserm_12558 (SIRIC ILIAD))
Article History
Received: 24 April 2020
Accepted: 5 August 2020
First Online: 21 August 2020
Compliance with ethical standards
:
: Dr. Goldenberg was Chairman of the Board and Chief Scientific Officer of Immunomedics, Inc., a publicly traded company, at the time this research was conducted, and was also a stockholder in the company. Immunomedics contributed materials to the study. Dr. Goldenberg is a patent inventor and is eligible to receive royalties from Immunomedics. Dr. Goldenberg was Chairman of the Board of IBC Pharmaceuticals, Inc., at the time this research was conducted. IBC Pharmaceuticals contributed materials to the study. Dr. Sharkey was an employee of Immunomedics during this study and also held stock options. Other authors have no conflict of interest to disclose.
: The trial sponsored by the Nantes University Hospital was approved by the responsible ethics committee (CPP) and registered at ExternalRef removed (NCT02587247). All patients signed informed consent.